Investment
Features
FeesSafety
Academy
More
Pluang+

US Treasury sanctions $24B scam platform Xinbi as it shifts from Tether to rival stablecoin USDD

Market News
09 Sep 2026
Unchained
View Source
Bearish
US Treasury sanctions $24B scam platform Xinbi as it shifts from Tether to rival stablecoin USDD

The US Treasury Department sanctioned Xinbi Guarantee, a Chinese-language scam marketplace that processed over $24 billion since 2022, accusing it of transnational criminal activity. Xinbi took over customers from the shut-down Huione Pay and moved to avoid law enforcement by shifting to encrypted messaging and a new wallet. Authorities froze $52.8 million in Tether wallets linked to Xinbi and seized infrastructure and digital wallets. Xinbi responded by condemning Tether's freezes and switching to USDD, a stablecoin without freeze controls. This crackdown highlights ongoing efforts to disrupt Southeast Asia-based crypto scams targeting US victims.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
54 minutes ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
1 hour ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
2 hours ago
NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...

Analyst Insights
Bullish
3 hours ago
Bitcoin hits predicted peak of $126K on Oct 6, 2025; next bottom forecasted for Oct 5, 2026 near $86K.

Bitcoin hits predicted peak of $126K on Oct 6, 2025; next bottom forecasted for Oct 5, 2026 near $86K.

A 4chan post from December 2023 accurately predicted Bitcoin's all-time high of around $126,000 on October 6, 2025, based on a 364-day market cycle pattern. Following the peak, Bitcoin dropped about 52% by mid-2026 but has since recovered to roughly ...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App